JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect Meeting Abstract


Authors: Hyman, D. M.; Zelnak, A. B.; Bauer, T. M.; Ulahannan, S. V.; Ford, J. M.; Cesari, R.; Hoyle, M.; Chappey, C.; Stewart, R.; Conte, U.; Yap, T. A.
Abstract Title: JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti-PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect
Meeting Title: 55th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 37
Issue: 15 Suppl.
Meeting Dates: 2019 May 31-Jun 4
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2019-05-20
Start Page: 144s
Language: English
ACCESSION: WOS:000487345803277
DOI: 10.1200/JCO.2019.37.15_suppl.TPS2660
PROVIDER: wos
Notes: Meeting Abstract: TPS2660 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Hyman
    354 Hyman